Boundless Bio Stock

boundlessbio.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $252.05MM

Boundless Bio, founded in 2018, is a biopharmaceutical company that develops novel cancer therapeutics seeking to understand and treat intractable cancers. Boundless Bio aims to interrogate extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers. Boundless Bio is headquartered in La Jolla, California.

Register To Buy and Sell Shares

For more details on financing and valuation for Boundless Bio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Boundless Bio’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Boundless Bio.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Boundless Bio investors also invested in these private companies

Cambridge Innovation Capital
Sectoral Asset Management
National Cancer Institute
Vertex Ventures HC
City Hill Ventures
Tavistock Group
PFM Health Sciences
GT Healthcare Capital Partners
Citadel Enterprise Americas


Management Team

Zachary Hornby
Chief Executive Officer & President
Christian Hassig Ph.D
Chief Scientific Officer
Neil Abdollahian
Chief Business Officer
Jonathan Lim MD
Benjamin Cravatt Ph.D
Klaus Wagner Ph.D
Chief Medical Officer

Board Members

Christine Brennan Ph.D
Vertex Ventures HC
Fabio Pucci Ph.D
RA Capital Management
Kristina Burow
ARCH Venture Partners

News Highlights

Boundless ups fundraising by Leaps and bounds, adding another $100M haul
Boundless Bio, the precision oncology company working on treatments for oncogene-amplified cancers, is amping up its fundraising with a new $100 million series C round backed by Leaps by Bayer and RA Capital Management.
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification
Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancer, today announced that the first patient has been dosed with BBI-355 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic solid tumors with oncogene amplifications (NCT05827614).
Updated on: Apr 23, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.